Assessment of Progressive Lens Designs (TBPD)

September 28, 2021 updated by: Silvia Tavazzi, University of Milano Bicocca
Non-invasive double-blind randomised comparative study on presbyopic subjects wearing progressive lenses.

Study Overview

Detailed Description

Background and rationale:

Nowadays many different types of progressive addition lenses are available for the correction of presbyopia. Progressive addition lenses provide a more natural correction for presbyopic people due to a gradual and progressive increase of lens power from far area through the intermediate portion to the near area. However, some patients still experience adaptation problems.

The primary purpose of the study is to evaluate the preference, adaptability and visual performance of progressive lens designs (up to three designs).

Study procedures:

Each participant is required to wear all pairs of spectacles one after another, each pair for one week.

Each participant will be required to visit the optometry clinic (at University of Milano Bicocca) three times:

Visit #1: Screening based on inclusion criteria, Informed Consent Form (ICF) form signing, Optometric exam and choice of the frame.

Subjects who will pass the inclusion/exclusion screening will be asked to sign the ICF and enrolled for the optometric exam. Subjects will choose the spectacle frame and all individual fitting parameters will be measured for lens' manufacturing.

Visit #2: Subjects will receive three marked pairs of progressive lenses. The three spectacle frames will be adjusted to fit properly on the subject' face. After 10-15 min of wearing of the first pair of lenses, each subject will be asked to answer to a questionnaire.

Visit #3 (last visit): questionnaires should be returned; the last comparison question will be answered during this visit, and subject will choose the best pair.

At the end of the study each participant will be entitled to get one pair of progressive lenses available in the market.

Subject population:

Presbyopic subjects have been already wearing any progressive additional lens (PAL) designs.

Number of Subjects:

40 +/- 2 subjects, the specified PAL design wearers and 40 +/- 2 the other PAL design wearers to be enrolled and signed the informed consent form.

Each subject will be wearing three different PAL designs. Subjects will be asked to choose one pair of spectacles (design) which they like the most.

Randomisation:

This study adopts a stratified permuted block randomisation to reduce an evaluation bias by the wearing sequence and prescriptions. The mean of both eyes' prescriptions is set as a single stratification factor.

Frames:

Each subject will choose a model of spectacle frame. Three identical frames will be taken for each subject.

Lenses:

  1. Lenses will be produced in EU
  2. Three different lens designs will be tested in the study.

Study Type

Interventional

Enrollment (Actual)

80

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Milano, Italy, 20126
        • Optics and Optometry of Milano-Bicocca (COMiB), Department of Materials Science - University of Milano-Bicocca

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

45 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Subjects should be experienced progressive lens designs wearers who have worn their current prescription for at least the last one month.
  2. PAL wearers with 14 mm corridor
  3. Age: 45 to 70 years old
  4. Best Corrected Monocular visual Acuity (decimal) both at distance and near ≥ 1.0;
  5. Normal binocular vision at distance & near:

    • no strabismus on cover test,
    • no fixation disparity (Mallett aligning prism of less than 2Δ horizontally or vertically) at near
    • stereoacuity of 60" or better at near;
  6. New prescription (found at visit #1) is in the range:

    • Spherical power: up to +/-6.00;
    • Cylindrical power: minus cylinder ≤ 2.5D;
    • Addition: 1.50-2.50D;
    • Difference in the power (spherical equivalent) between eyes: up to 2.0D
  7. Understanding and speaking Italian or English to be able to answer questionnaires
  8. Giving a written consent to participate in the study

Exclusion Criteria:

  1. First prescription for progressive lenses.
  2. Prescription found during visit#1 varies from current prescription more than 0.50D in any meridian
  3. Wearing Single Vision lenses with accommodative support
  4. Double vision or prismatic prescription in current glasses;
  5. Known ocular disease including strabismus, any pathology, any eye surgeries that may affect visual acuity
  6. Use of systemic or ocular medications that are likely to affect vision
  7. Balance problem/vertigo problem
  8. Concurrent participation in other vision-related research

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: The other PAL design wearers
Subjects who have been already wearing any from the other design type of PAL
Subjects will be wearing three different PAL designs with different geometries of the optical progression.
Experimental: The specified PAL design wearers
Subjects who have been already wearing any from specified design type of PAL
Subjects will be wearing three different PAL designs with different geometries of the optical progression.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evaluate the preference among progressive lens designs
Time Frame: Entire study duration (approx. 4 weeks)
Evaluate the preference among progressive lens designs through a "First impression questionnaire" after 10-15 minutes of wearing each of the 3 PALs, a "Final satisfaction questionnaire" after 1 week of use of each of the 3 PALs and a "Comparison questionnaire" at the end of the three trial periods of all the three types of PALs.
Entire study duration (approx. 4 weeks)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evaluate the adaptability of progressive lens designs.
Time Frame: Entire study duration (approx. 4 weeks)
Evaluate adaptability of progressive lens designs through a "Final satisfation questionnaire" after one week of use of each of the three PALs.
Entire study duration (approx. 4 weeks)
Evaluate visual performance of progressive lens designs.
Time Frame: Entire study duration (approx. 4 weeks)
Evaluate the visual performance of progressive lens designs measured both after 10-15 minutes of wear and after one week by psychophysical analysis (visual acuity at high contrast at near and at distance, rate/accuracy of reading test at high contrast and at near).
Entire study duration (approx. 4 weeks)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 19, 2020

Primary Completion (Actual)

August 31, 2021

Study Completion (Actual)

September 20, 2021

Study Registration Dates

First Submitted

January 15, 2021

First Submitted That Met QC Criteria

January 27, 2021

First Posted (Actual)

February 2, 2021

Study Record Updates

Last Update Posted (Actual)

September 29, 2021

Last Update Submitted That Met QC Criteria

September 28, 2021

Last Verified

September 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2019-01 (Other Identifier: NANT)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Presbyopia

Clinical Trials on Progressive Additional Lenses (PAL), pre calibrated and made of polymeric material with anti-reflection coating

3
Subscribe